The present invention relates to a MuSK agonist antibody, or a VH, VL or CDR3 thereof, a polynucleotide encoding said antibody or a VH, VL or CDR3 thereof or an expression vector comprising said polynucleotide or a composition comprising said antibody, polynucleotide or expression vector and their use in methods of preventing and treating diseases and conditions associated with an impaired neuromuscular transmission.

The present application is directed to heterodimeric antibodies and methods of use.

The present application provides anti-B7-H4 constructs that bind to B7-H4 (e.g., anti-B7-H4 antibodies), nucleic acid molecules encoding an amino acid sequence of the anti-B7-H4, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of preparing the anti-B7-H4 construct, pharmaceutical compositions containing the anti-B7-H4 construct, and methods of using the anti-B7-H4 construct or compositions.

Provided herein are a combination of antitumor medicaments comprising a TRAIL-R2 agonistic antibody (e.g., CTB006) and Ponatinib or its hydrochloride. Also provided herein are a method of treating tumors that include administering therapeutically effective amounts of a TRAIL-R2 agonistic antibody and Ponatinib or its hydrochloride to a patient. The synergistic effect of these two medicaments helps to enhance the effect of tumor treatment.

Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Methods and compounds for conferring site-specific or local immune privilege.

The present disclosure provides anti-OX40 antibodies, and antigen-binding portions thereof. In certain embodiments, the antibodies or fragments thereof, are used for the treatment of cancer.

A PD-1/CD4 bispecific protein for preventing, suppressing the progression of symptoms of or the recurrence of or treating autoimmune diseases, hematological cancer and the like, which can reduce the induction of cytokine production or release upon administration, and thus is expected to inhibit the development of infusion reactions or cytokine release syndrome after administration.

The present invention relates to a bifunctional molecule comprising an anti-PD-1 antibody and IL-7 and its uses.

Described are anti-LILRB3 antibody molecules, such as agonistic anti-LILRB3 antibody molecules for use in treatment of graft rejection or autoimmunity via reprograming of human myeloid cells. Described are also specific anti-LILRB3 antibody molecules and use of such antibody molecules in medicine, for example in treatment of graft rejection, autoimmune disorders or inflammatory disorders.